Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Flavopiridol in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies
This study has been suspended.
Study NCT00070239 Information provided by National Cancer Institute (NCI)
First Received: October 3, 2003 Last Updated: January 28, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Breast Cancer
Head and Neck Cancer
Intraocular Melanoma
Kidney Cancer
Leukemia
Lung Cancer
Lymphoma
Malignant Mesothelioma
Melanoma (Skin)
Sarcoma
Small Intestine Cancer
Additional conditions recognized in this trial
Breast Neoplasms
Carcinoma, Renal Cell
Duodenal Neoplasms
Eye Neoplasms
Head and Neck Neoplasms
Hematologic Neoplasms
Ileal Neoplasms
Intestinal Neoplasms
Jejunal Neoplasms
Kidney Neoplasms
Lung Neoplasms
Melanoma
Mesothelioma
Multiple Myeloma
Neoplasms
Neoplasms, Plasma Cell
More general conditions related to this trial
Adenocarcinoma
Adenoma
Blood Protein Disorders
Breast Diseases
Carcinoma
Cardiovascular Diseases
Digestive System Diseases
Digestive System Neoplasms
Duodenal Diseases
Eye Diseases
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Ileal Diseases
Immune System Diseases
Immunoproliferative Disorders
Intestinal Diseases
Jejunal Diseases
Kidney Diseases
Lung Diseases
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Connective and Soft Tissue
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Mesothelial
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas
Paraproteinemias
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Skin Diseases
Thoracic Neoplasms
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Vascular Diseases
Interventions listed in this trial
alvocidib
Additional drug interventions recognized in this trial
Flavopiridol
More general drug interventions related to this trial
Antineoplastic Agents
Enzyme Inhibitors
Growth Inhibitors
Growth Substances
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
Back to top of Main Content
